Stockreport

Inovio announces U.S. FDA accepted BLA for INO-3107 [Yahoo! Finance]

Inovio Pharmaceuticals, Inc.  (INO) 
NASDAQ:AMEX Investor Relations: ir.inovio.com/investors/default.aspx
PDF The review classification designated by FDA is Standard. The FDA assigned INO-3107 a Prescription Drug User Fee Act, PDUFA, review goal date of October 30, 2026, which i [Read more]